155 related articles for article (PubMed ID: 22114500)
1. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.
Crielaard BJ; van der Wal S; Lammers T; Le HT; Hennink WE; Schiffelers RM; Storm G; Fens MH
Int J Nanomedicine; 2011; 6():2697-703. PubMed ID: 22114500
[TBL] [Abstract][Full Text] [Related]
2. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics.
Crielaard BJ; van der Wal S; Le HT; Bode AT; Lammers T; Hennink WE; Schiffelers RM; Fens MH; Storm G
Eur J Pharm Sci; 2012 Mar; 45(4):429-35. PubMed ID: 21907797
[TBL] [Abstract][Full Text] [Related]
3. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
[TBL] [Abstract][Full Text] [Related]
4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
5. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
[TBL] [Abstract][Full Text] [Related]
7. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
8. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
[TBL] [Abstract][Full Text] [Related]
9. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.
Atkinson JM; Falconer RA; Edwards DR; Pennington CJ; Siller CS; Shnyder SD; Bibby MC; Patterson LH; Loadman PM; Gill JH
Cancer Res; 2010 Sep; 70(17):6902-12. PubMed ID: 20663911
[TBL] [Abstract][Full Text] [Related]
10. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation.
Fournier-Dit-Chabert J; Vinader V; Santos AR; Redondo-Horcajo M; Dreneau A; Basak R; Cosentino L; Marston G; Abdel-Rahman H; Loadman PM; Shnyder SD; Díaz JF; Barasoain I; Falconer RA; Pors K
Bioorg Med Chem Lett; 2012 Dec; 22(24):7693-6. PubMed ID: 23103097
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Pan D; Schmieder AH; Wang K; Yang X; Senpan A; Cui G; Killgore K; Kim B; Allen JS; Zhang H; Caruthers SD; Shen B; Wickline SA; Lanza GM
Theranostics; 2014; 4(6):565-78. PubMed ID: 24723979
[TBL] [Abstract][Full Text] [Related]
13. Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy.
Durrant DE; Richards J; Tripathi A; Kellogg GE; Marchetti P; Eleopra M; Grisolia G; Simoni D; Lee RM
Invest New Drugs; 2009 Feb; 27(1):41-52. PubMed ID: 18516499
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).
Cai YC; Zou Y; Ye YL; Sun HY; Su QG; Wang ZX; Zeng ZL; Xian LJ
Invest New Drugs; 2011 Apr; 29(2):300-11. PubMed ID: 20012336
[TBL] [Abstract][Full Text] [Related]
15. Discovery of dihydrofuranoallocolchicinoids - Highly potent antimitotic agents with low acute toxicity.
Shchegravina ES; Svirshchevskaya EV; Combes S; Allegro D; Barbier P; Gigant B; Varela PF; Gavryushin AE; Kobanova DA; Shchekotikhin AE; Fedorov AY
Eur J Med Chem; 2020 Dec; 207():112724. PubMed ID: 32827941
[TBL] [Abstract][Full Text] [Related]
16. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway.
Niu G; Sun L; Pei Y; Wang D
Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844
[TBL] [Abstract][Full Text] [Related]
17. Design and preparation of pH-sensitive cytotoxic liposomal formulations containing antitumor colchicine analogues for target release.
Shchegravina ES; Tretiakova DS; Sitdikova AR; Usova SD; Boldyrev IA; Alekseeva AS; Svirshchevskaya EV; Vodovozova EL; Fedorov AY
J Liposome Res; 2024 Sep; 34(3):399-410. PubMed ID: 37867342
[TBL] [Abstract][Full Text] [Related]
18. Lipophilic prodrugs of a triazole-containing colchicine analogue in liposomes: biological effects on human tumor cells.
Kuznetsova NR; Svirshchevskaya EV; Sitnikov NS; Abodo L; Sutorius H; Zapke J; Velder J; Thomopoulou P; Oschkinat H; Prokop A; Schmalz HG; Fedorov AY; Vodovozova EL
Bioorg Khim; 2013; 39(5):609-18. PubMed ID: 25702420
[TBL] [Abstract][Full Text] [Related]
19. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.
Nicholson B; Lloyd GK; Miller BR; Palladino MA; Kiso Y; Hayashi Y; Neuteboom ST
Anticancer Drugs; 2006 Jan; 17(1):25-31. PubMed ID: 16317287
[TBL] [Abstract][Full Text] [Related]
20. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
